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Abstract 23 
China is one of countries with the highest prevalence of fluoroquinolones 24 
resistant (FQr) Mycobacterium tuberculosis. Nevertheless, the knowledge 25 
on molecular characterization of FQr M. tuberculosis strains of this region 26 
remains very limited. 27 
This study was to investigate the frequencies and types of mutations 28 
present in FQr M. tuberculosis clinical isolates collected in Shanghai, 29 
China. 30 
A total of 206 FQr M. tuberculosis strains and 21 ofloxacin sensitive (FQs) 31 
M. tuberculosis strains were isolated from patients with pulmonary 32 
tuberculosis in Shanghai. The phenotypic drug susceptibilities were 33 
determined by the proportion method and the mutations inside 34 
quinolone-resistance-determining region (QRDR) of gyrA and gyrB genes 35 
were identified by DNA sequence analyses. 36 
Among 206 FQr M. tuberculosis strains, 44% (90/206) were multi-drug 37 
resistant (MDR) isolates and 39% (81/206) were extensive drug resistant 38 
(XDR) isolates. Only 9% (19/206) were mono-resistant to Ofloxacin. In 39 
total, 79.1% (163/206) of FQr isolates harboured mutations in either gyrA 40 
or gyrB QRDR. Mutations in gyrA QRDR were found in 75.7% (156/206) 41 
FQr clinical isolates. Among those gyrA mutants, a majority (75.6%) 42 
harboured mutations at amino acid position 94, with D94G being the 43 
most frequent amino acid substitution. Mutations in gyrA QRDR showed 44 
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100% positive predictive value for FQr M. tuberculosis in China. 45 
Mutations in gyrB were observed in 15.5% (32/206) of FQr clinical 46 
isolates. Ten novel mutations were identified in gyrB. However, most of 47 
them also harboured mutations in gyrA, limiting their contribution to FQr 48 
resistance in M. tuberculosis. 49 
Our findings indicated that, similar to other geographic regions, 50 
mutations in gyrA showed to be the major mechanism of FQr resistance in 51 
M. tuberculosis isolates. The mutations in gyrA QRDR can be a good 52 
molecular surrogate marker for detecting FQr M. tuberculosis in China.  53 
 54 
1 Introduction  55 
In the last decades, tuberculosis (TB) remains one of the major 56 
life-threatening diseases worldwide due to the emergence of 57 
multidrug-resistant TB (MDR-TB) and extensively drug-resistant 58 
TB(XDR-TB) . MDR-TB is defined as M. tuberculosis strains that are 59 
resistant to both isoniazid and rifampin (World Health Organization, 60 
2011) .Globally, about 440,000 MDR-TB cases is estimated to emerge, 61 
and 150,000 persons died with MDR-TB each year (World Health 62 
Organization, 2011). A recent report showed an alarming increase in the 63 
number of tuberculosis patients in the South Asian subcontinent, with 64 
China being singled out as having one of the greatest burdens of 65 
MDR-TB, with a poor prognosis and high mortality among HIV-infected 66 
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individuals (World Health Organization, 2010). XDR-TB is defined as 67 
MDR-TB strains which are further resistant to any fluoroquinolone (FQ) 68 
and any of the second-line anti-TB injectable drugs (amikacin, kanamycin 69 
or capreomycin) (World Health Organization, 2011). By March 2011, 69 70 
countries, including China, had reported to WHO with at least one case of 71 
XDR-TB. There is an estimated 25,000 cases of XDR-TB emerging every 72 
year (World Health Organization, 2010).  73 
Fluoroquinolones, which are the backbone drugs for MDR-TB treatment 74 
has been introduced into clinical practices in China since late 1980s (Xu 75 
et al., 2009). It has been widely used in treatment for undiagnosed 76 
respiratory bacterial infections for more than two decades. Since TB 77 
patients are not treated normatively, FQ-resistant (FQr) TB has become 78 
more prevalent in China (Hu et al., 1992, Jiang, 1992, Vien le et al., 2011, 79 
Wise, 2003, Xu et al., 2009, Zhou et al.,2011). Although the molecular 80 
characterization of fluoroquinolone resistance (FQr) in Mycobacterium 81 
tuberculosis has been well studied in our neighbouring regions such as 82 
Hong Kong, Taiwan and Russia (Chan et al., 2007, Huang et al., 2005, 83 
Lau et al., 2011, Mokrousov et al., 2008, Umubyeyi et al.,2007)，only a 84 
few studies based on limited strains of FQr Mycobacterium tuberculosis 85 
were reported for China (Cui et al., 2011, Sun et al., 2007, Xu et 86 
al.,2009).   87 
This study recruited a large cohort of FQr M. tuberculosis clinical isolates 88 
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from Shanghai and its neighbouring cities in China to provide a 89 
conclusive and representative figures for molecular characterization of 90 
FQr M. tuberculosis using sequence analyses of the drug target genes for 91 
fluoroquinolones, gyrA and gyrB.    92 
 93 
2 Materials and methods:  94 
2.1 Selection of M. tuberculosis clinical isolates and drug 95 
susceptibility test. All M. tuberculosis isolates were originally isolated 96 
from patients with pulmonary tuberculosis in the period of 32 months 97 
(September 2007 – April 2010). These patients were descriptive 98 
epidemiologically unlinked and originated from third-grade hospitals in 99 
Shanghai and its neighboring cities in China. All strains were cultured on 100 
Löwenstein-Jensen medium and identified by niacin accumulation test 101 
and nitrate reduction test (Clinical and Laboratory Standards Institute, 102 
2008). The phenotypic susceptibilities of these isolates to major first-line 103 
drugs: isoniazid (INH) (0.2μg/mL), rifampin (RIF) (40μg/mL) and 104 
ethambutol (EMB) (2μg/mL) as well as the seondary drug streptomycin 105 
(STR) (4μg/mL) were examined by using the Löwenstein-Jensen medium 106 
proportion method (World Health Organization, 2001). Three second-line 107 
drugs were chosen for MDR-TB treatment in Shanghai and drug 108 
susceptibility tests were performed by Bactec MGIT 960,using the 109 
following concentrations: ofloxacin (OFX) (2.0 μg/ml), capreomycin 110 
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(CAP) (2.5 μg/ml), amikacin (AMK) (1.0μg/ml) (World Health 111 
Organization, 2008) .A total of 206 ofloxacin-resistant strains were 112 
obtained and selected for this project. Of these 206 ofloxacin-resistant 113 
strains, 56 were isolated from new cases whereas 150 were isolated from 114 
re-treated case. A additional 21 ofloxacin-susceptible strains were also 115 
randomly selected as the denominators for molecular characterization of 116 
FQr M. tuberculosis strains in this project.  117 
 118 
2.2 DNA extraction. A loopful of M. tuberculosis colonies was collected 119 
from Löwenstein-Jensen slant and suspended in sterilized water to 120 
provide bacterial suspension of McFarland standard 1. The suspension 121 
was centrifuged at 10,000× g for 5 min. The supernatant was discarded 122 
and the sediment was resuspended in a 40 μl DNA extraction solution 123 
(QIAGEN,Hilden,Germany) by vortex. Subsequently, the tube was 124 
incubated at 100℃ for 15 min, followed by centrifugation at 13,000 × g 125 
for 10 min. The supernatant was ready for PCR and was preserved at 126 
-20℃ until use. 127 
 128 
2.3 gyrA and gyrB PCR-sequencing. PCR-sequencing protocols were 129 
performed to detect mutations in fluoroquinolones-resistance determining 130 
regions (QRDR) in gyrA and gyrB according to Lau et al (Lau et al, 2011). 131 
The DNA sequences were assembled and edited by using BioEdit 132 
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software version 7.0.5.3. The genetic polymorphisms of gyrA and gyrB 133 
were compared with those sequences of M. tuberculosis strain H37Rv in 134 
GenBank accession number: NC_000962.2 (Takiff et al, 2004).  135 
 136 
3. Results:  137 
3.1 Drug susceptibility profiles. The 206 FQ-resistant isolates were 138 
tested for susceptibility to INH, RIF, STR, and ETH. A total of 43.9% (n 139 
= 90/206) of isolates were MDR and 39.3% (n=81/206) belonged to XDR. 140 
The drug susceptibility profiles of the 206 FQ-resistant isolates with 141 
different gyrA/B mutations patterns were shown in table 1.  142 
Among 21 ofloxacin-susceptible strains, 76.2% (n=16/21) of them were 143 
pan-susceptible, 19.0% (n=4/21) were mono-resistant (one was resistant 144 
to STR and three were resistant to INH) while 4.8% (n=1/21) of isolates 145 
were resistant to both STR and INH.  146 
 147 
3.2 Distribution of gyrA mutations among M. tuberculosis clinical 148 
isolates. The gyrA QRDR PCR were amplified successfully for all 227 149 
isolates. Upon sequence analyses, no deletion and insertion were found. 150 
All the strains possessed a natural polymorphism at amino acid position 151 
95 with serine substituted by thronine (AGC  ACC), which had shown 152 
to be unrelated to fluoroquinolone- resistance in M. tuberculosis 153 
(Ginsburg et al, 2003).  None of 21 FQs isolates harboured 154 
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resistance-associated mutation in gyrA QRDR, whereas 156 of 206 FQr 155 
clinical isolates harboured resistance-associated mutations in this region, 156 
given the specificity and sensitivity to be 100% and 75.7% respectively.  157 
Among the 156 gyrA mutants, 151 harbored single mutation at amino 158 
acid positions 88, 90, 91 or 94 whereas 5 showed double mutations in 159 
both 90 and 91or both 90 and 94.  160 
Position 94 was the most frequent resistance-associated mutation site 161 
found in FQr clinical isolates, resulting in seven different amino acid 162 
substitutions: D94G (n = 57), D94A (n = 23), D94C(n=2) D94Y (n = 1), 163 
D94N(n = 20), D94V(n = 1) and D94H (n = 3), and accounted for 57.3% 164 
of fluoroquinolone- resistance in M. tuberculosis isolates. Position 90 is 165 
the second most prevalent mutation site, which accounted for 16% of FQr 166 
clinical isolates. The mutation patterns of gyrA QRDR among 206 FQr 167 
clinical isolates were shown in table 2.  168 
Among 156 gyrA mutants, 61 (39.1%) were XDR and 74 (47.3%) were 169 
MDR, accounting for 75.3% (61/81）XDR and 82.2% (74/90)MDR FQr 170 
M .tuberculosis in our collection Table 1.   171 
 172 
3.3 Distribution of gyrB mutations among  M. tuberculosis clinical 173 
isolates. The gyrB QRDR PCR were also amplified successfully for 174 
isolates. Among 206 ofloxacin-resistant M. tuberculosis clinical isolates, 175 
32 of them harboured mutations in gyrB gene. Of them, 78.1%(n=25/32) 176 
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also harboured mutations in gyrA QRDR. No gyrB mutations were found 177 
in those 21 FQs isolates. A total of 18 amino acid substitutions were found 178 
in gyrB gene, with position 424 being the most frequent mutation site 179 
(Table 2). Among the 18 amino acid substitutions, 10 were novel 180 
mutations (Table 2) that were first reported in this study.  181 
Among 32 gyrB mutants, 13 (40.6%) were XDR and 17 (53.1%) were 182 
MDR, accounting for 16% (13/81）XDR and 18.9% (17/90)MDR FQr M. 183 
tuberculosis in our collection (Table 1). 184 
 185 
4. Discussion 186 
Despite continued efforts directed to improve tuberculosis control 187 
programs at national level, China remains as a major region with the 188 
greatest burden of MDR-TB. In addition to resistance towards INH and 189 
RIF, 27.4% of MDR-TB also showed resistance to FQ, which is the most 190 
potent drug against MDR-TB.  This may reflect the extensive usage of 191 
FQ in treatment for undiagnosed bacterial infections in China (Jiang, 192 
1992, World Health Organization, 2010).  193 
In present study, a total of 75.7% of FQr isolates were showed to harbour 194 
mutations in gyrA QRDR, with amino acid position 94 being the most 195 
predominant mutation site. The reported frequency is similar to that in 196 
Hong Kong (75%) and that in Rwanda (75%) although it is lower than 197 
that in Russia (83%) and higher than that in Taiwan (50%) (Chan et al., 198 
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2007, Huang et al., 2005, Mokrousov et al., 2008, Umubyeyi et al.,2007), 199 
showing that mutations in gyrA QRDR was the key factor leading to 200 
quinolone-resistance in M. tuberculosis in China. 201 
As reported in other studies (Huang et al, 2005, Lau et al, 2011, 202 
Mokrousov et al, 2008), gyrB QRDR mutations only accounted for a 203 
minority of FQr M. tuberculosis. Ten novel mutations were found in this 204 
study. However, transformation studies are needed to confirm their 205 
contribution in FQr M. tuberculosis.  206 
In this study, we recruited a large cohort of 206 FQr M. tuberculosis 207 
clinical isolates to investigate the types and frequencies of gyrA and gyrB 208 
mutations in FQr M. tuberculosis circulating in China. Our findings are 209 
highly representative for molecular patterns of FQr M. tuberculosis in this 210 
region. A previous study with fewer FQr M. tuberculosis samples reported 211 
that only 8% of their strains had neither gyrA nor gyrB mutations (Cui et 212 
al., 2011). However, this study revealed more than 20.9% of our FQr 213 
isolates harbored no known FQ resistance mechanisms, indicating that 214 
more comprehensive information would be available when more strains 215 
are included for investigation.  216 
For those isolates with no known mutations, it has been suggested that the 217 
mechanism for resistance in such isolates may be mediated by active 218 
efflux pumps, as in vitro studies have shown that the use of efflux pump 219 
inhibitors resulted in the reduction of MIC levels of FQ (Escribano et al, 220 
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2007, Louw et al, 2011, Singh et al, 2011). 221 
Although development of FQr is a critical step for a MDR strain 222 
converting to be XDR, either gyrA or gyrB alone, or in combination, did 223 
not represent as a reliable marker for predicting XDR-TB, with more than 224 
50% gyrA or gyrB mutants are non-XDR strains. Amikacin resistance and 225 
capreomycin resistance are also the important criteria in defining 226 
XDR-TB. Mutations in the 1400 region of rrs have been detected in 227 
isolates that are resistant to these drugs. Detection of both gyrA and rrs 228 
mutations may be more reliable for prediction of XDR phenotype.  229 
In conclusion, our study indicated that the molecular characterization in 230 
FQr M. tuberculosis collected in China is similar to those reported 231 
elsewhere, with mutations in gyrA QRDR being the most predominant 232 
resistance determinant. PCR-sequencing of gyrA QRDR is a reliable 233 
molecular detection marker for FQr M. tuberculosis in China 234 
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 330 
Table 1: The association between drug resistance patterns and mutations in gyrA and gyrB in 206 
FQ-resistant isolates.  
  
Resistance Patterna   gyrA only gyrB only gyrA + gyrB Non-gyrA nor gyrB Total 
FQ only 
 
6 0 0 10 16 
FQ, INH 
 
3 0 0 1 4 
FQ, STR 
 
1 0 0 0 1 
FQ, EMB 
 
1 0 0 0 1 
FQ, CAP 
 
1 0 1 0 2 
FQ, INH, STR 
 
3 0 0 0 3 
FQ, INH, EMB,AMK 
 
0 0 0 1 1 
FQ, INH, STR, EMB 
 
1 0 0 0 1 
FQ, INH, STR,AMK 
 
1 0 0 0 1 
FQ, INH,STR,AMK,CAP 
 
0 0 0 1 1 
FQ, INH,CAP 
 
0 0 1 0 1 
FQ, RIF, STR, EMB 
 
1 0 0 0 1 
FQ,AMK,CAP 
 
1 0 0 0 1 
FQ, EMB,AMK,CAP 
 
0 0 0 1 1 
FQ, MDR 
 
59 2 15 14 90 
XDR   53 5 8 15 81 
Total 
 
131 7 25 43 206 
a FQ: Fluoroquinolones; INH: Isoniazid; STR: Streptomycin; EMB: Ethambutol; CAP: Capreomycin; AMK: 331 
Amikacin; RIF: Rifampcin; MDR: Multidrug resistance which is defined as M. tuberculosis strains that 332 
are resistant to both isoniazid and rifampin; XDR: Extensively drug-resistance which is defined as 333 
MDR-TB strains which are further resistant to any fluoroquinolone and any of the second-line anti-TB 334 
injectable drugs (amikacin, kanamycin or capreomycin) 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
346 
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Table 2: Mutation patterns in gyrA and gyrB identified in 206 FQ-resistant isolates by 347 
sequencing 348 
gyrA mutation gyrB mutation No. of isolates(%) 
A90V Wild type 28(13.59) 
A90V S91P Wild type 3(1.47) 
A90V D94H Wild type 1(0.49) 
A90V D94N Wild type 1(0.49) 
S91P Wild type 5(2.4) 
S91P N464S 1(0.49) 
D94A Wild type 14(6.8) 
D94A T465P* 2(0.97) 
D94A N464T* 2(0.97) 
D94A N464K 1(0.49) 
D94A I458M 1(0.49) 
D94A E481Q D483H 1(0.49) 
D94A E424K* 1(0.49) 
D94C Wild type 2(0.97) 
D94G Wild type 46(22.3) 
D94G E424K* 4(1.9) 
D94G A469V* 1(0.49) 
D94G E522Q* 3(1.47) 
D94G D414P* 1(0.49) 
D94G D414K* 1(0.49) 
D94G R457G 1(0.49) 
D94H Wild type 3(1.47) 
D94N Wild type 17(8.25) 
D94N N464S* 1(0.49) 
D94N V461A 1(0.49) 
D94N E419K* E424K* R460K 1(0.49) 
D94V N464T* 1(0.49) 
D94Y Wild type 9(4.37) 
D94Y E419K* 1(0.49) 
G88A Wild type 1(0.49) 
Wild type S434A 1(0.49) 
Wild type E424K* 4(1.9) 
Wild type G425E 1(0.49) 
Wild type E419K* T465P* 1(0.49) 
Wild type Wild type 43(20.9) 
  206(100) 
*: Novel mutations 349 
 350 
